Randomised controlled trial of Levosimendan vs Enoximone in Cardiogenic Shock

INTERVENTION: Following assessment by the duty Consultant Intensivist invasive monitoring will be placed as part of the current standard clinical practice. All those satisfying both the inclusion and exclusion criteria will be randomised to receive either Levosimendan or Enoximone infusions, subject to obtaining their consent. The rate of loading dose and subsequent 24 hour infusion will be based on a standardised protocol. Cardiovascular parameters will be taken immediately before commencement of infusions to establish baseline readings. This data will be collected at 10 minutes, 1, 4, 6, 12 and 24 hours after starting the infusions. All members of staff will be blinded to the type of infusion given. Standard demographic and biochemical data will be collected from each patient. This will be collected on a standardised proforma by the investigators. CONDITION: Cardiovascular: Cardiogenic shock ; Circulatory System ; Cardiogenic shock PRIMARY OUTCOME: Not provided at time of registration SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Patients over 18 years of age. 2. All patients that are suspected of having cardiogenic shock during their admission to the Critical Care Unit will be identified.